Krystal Biotech (KRYS) Enterprise Value (2021 - 2025)
Krystal Biotech (KRYS) has disclosed Enterprise Value for 5 consecutive years, with -$827.8 million as the latest value for Q4 2025.
- Quarterly Enterprise Value fell 38.54% to -$827.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$827.8 million through Dec 2025, down 38.54% year-over-year, with the annual reading at -$827.8 million for FY2025, 38.54% down from the prior year.
- Enterprise Value hit -$827.8 million in Q4 2025 for Krystal Biotech, down from -$731.1 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$343.1 million in Q3 2021 to a low of -$827.8 million in Q4 2025.
- Historically, Enterprise Value has averaged -$512.5 million across 5 years, with a median of -$504.8 million in 2023.
- Biggest five-year swings in Enterprise Value: grew 19.38% in 2023 and later crashed 53.62% in 2024.
- Year by year, Enterprise Value stood at -$438.1 million in 2021, then increased by 13.45% to -$379.2 million in 2022, then tumbled by 40.35% to -$532.2 million in 2023, then dropped by 12.28% to -$597.5 million in 2024, then tumbled by 38.54% to -$827.8 million in 2025.
- Business Quant data shows Enterprise Value for KRYS at -$827.8 million in Q4 2025, -$731.1 million in Q3 2025, and -$682.0 million in Q2 2025.